MedPath

Breathlessness Assessment in Adult Patients With Myotonic Dystrophy Type 1

Completed
Conditions
Myotonic Dystrophy Type 1 (DM1)
Registration Number
NCT04835298
Lead Sponsor
CHU de Reims
Brief Summary

Myotonic dystrophy type 1 (DM1) is one of the most common neuromuscular diseases in adults. As respiratory dysfunction is the most common cause of death in patients with DM1, a respiratory disease progression must be monitored combining symptom screening and respiratory function testing, in order to identify the appropriate time to initiate non invasive ventilation (NIV).

Dyspnea, one of the main respiratory symptoms, has been little studied in patients with DM1.

The main objective of this study is to provide the first multidimensional description of dyspnea in patients with DM1.

The secondary objectives are:

* To compare respiratory symptoms according to the presence or not of criteria from respiratory function testing to initiate NIV

* To assess associations between dyspnea and respiratory function testing

* To assess associations between dyspnea and number of Cytosine Thymine Guanine (CTG) repeats

* To assess associations between dyspnea and muscular strength

* To assess associations between dyspnea and BMI

* To assess associations between dyspnea and anxiety or depression

* To assess associations between dyspnea and cognitive impairment

* To assess associations between dyspnea and quality of life.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
34
Inclusion Criteria
  • patient with myotonic dystrophy type 1 confirmed by genetic analysis
  • with an age older than 18 years
Exclusion Criteria
  • an ongoing or recent (i.e. within the last 4 weeks prior to study recruitment) medical condition, including pulmonary exacerbations
  • patient already under non-invasive mechanical ventilation

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
DyspneaMonth 6

Borg scale at rest and after 6 minute walking test

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Chu Reims

🇫🇷

Reims, France

Chu Reims
🇫🇷Reims, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.